Autoimmune disorders companion diagnostic - Novartis / Protagen

Drug Profile

Autoimmune disorders companion diagnostic - Novartis / Protagen

Latest Information Update: 10 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protagen AG
  • Class Antibody diagnostics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Autoimmune disorders

Most Recent Events

  • 20 Dec 2016 Clinical trials in Autoimmune disorders (Diagnosis) (unspecified route)
  • 20 Dec 2016 Protagen AG and Novartis complete a collaboration agreement to develop a companion diagnostic for Autoimmune disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top